Leaked data from Moderna Inc. and Merck & Co.’s melanoma vaccine trial has created an unusual divide between medical professionals and investors. Oncologists have hailed the results, while Wall Street reacted by selling off shares of both companies.
The trial results, which were prematurely shared on social media, sparked contrasting reactions ahead of the official presentation at the European Society for Medical Oncology meeting in Madrid. Typically, such pivotal drug studies yield clear outcomes that align the perspectives of doctors, patients, and investors. However, this time, the responses have diverged sharply.
The discrepancy highlights the complexity of interpreting clinical trial data. While doctors appear encouraged by the findings, financial markets have interpreted the same data as a negative signal, leading to a sell-off in Moderna and Merck shares.